MariMed Inc. (MRMD)
(Delayed Data from OTC)
$0.18 USD
+0.02 (11.11%)
Updated Sep 9, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
MariMed Inc. [MRMD]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: MariMed Inc.
Industry: Consulting Services
Operational Wins, But Mixed Q2/24 Results As Costs Continue to Climb
Provider: Ventum Capital Markets
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
Costs Weigh on Q124 Earnings, Though H224 Still Expected to Show
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
New Debt Facility Improves Liquidity Outlook, Positive for Shareholders
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
Solid Q422 Results and 2023 Guidance Ahead of Estimates, Cashed Up for Tuck-in M&A and Maryland Adult-Use Could Drive Further Upside
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Weekly ReHash: Cannabis Week - Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: MariMed Inc.
Industry: Consulting Services
Company: MariMed Inc.
Industry: Consulting Services
Savvy to Beef Up the Balance Sheet While Others Pull Back From the Dinner Table, Expecting Tuck-In M&A and Accelerated Growth Capex to Follow
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Weekly ReHash: Pricing is Key to Improving Industry Fundamentals
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: MariMed Inc.
Industry: Consulting Services
Mixed Q322 Results: Sales Outpacing Markets but Pricing Pressure Limits Margin Recovery; Revised Guidance Pushes Profitability Ramp to 2023
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Achieves Vertical Integration in Maryland Ahead of Likely Adult-Use Approval, Valuation Offers Attractive Entry Point
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Solid Q222 Sales But Surprise Margin Blip and Revised Guidance, Expecting Sales Growth and Higher Earnings in H222
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Q421 Results Strong Across the Board: Setting a High Standard in a Seasonally Weak Quarter
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Closes Acquisition of Kind Therapeutics, Consolidating Maryland Business Ahead of Likely Adult-Use Conversion
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: MariMed Inc.
Industry: Consulting Services
Q421 Results & Site Visit Notes: Solid Revenues, Margins a Tad Light but Reasons for Improvement Across 2022
Provider: Echelon Welath Partners
Analyst: SEMPLE A